+

WO2009148600A3 - Deuterated lysine-based compounds - Google Patents

Deuterated lysine-based compounds Download PDF

Info

Publication number
WO2009148600A3
WO2009148600A3 PCT/US2009/003391 US2009003391W WO2009148600A3 WO 2009148600 A3 WO2009148600 A3 WO 2009148600A3 US 2009003391 W US2009003391 W US 2009003391W WO 2009148600 A3 WO2009148600 A3 WO 2009148600A3
Authority
WO
WIPO (PCT)
Prior art keywords
based compounds
lysine
deuterated
deuterated lysine
compositions
Prior art date
Application number
PCT/US2009/003391
Other languages
French (fr)
Other versions
WO2009148600A2 (en
WO2009148600A8 (en
Inventor
Julie F. Liu
Scott L. Harbeson
Original Assignee
Concert Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concert Pharmaceuticals, Inc. filed Critical Concert Pharmaceuticals, Inc.
Publication of WO2009148600A2 publication Critical patent/WO2009148600A2/en
Publication of WO2009148600A8 publication Critical patent/WO2009148600A8/en
Publication of WO2009148600A3 publication Critical patent/WO2009148600A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/39—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/41—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention relates to novel lysine-based compounds, their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an HIV protease inhibitor.
PCT/US2009/003391 2008-06-06 2009-06-04 Deuterated lysine-based compounds WO2009148600A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5955608P 2008-06-06 2008-06-06
US61/059,556 2008-06-06

Publications (3)

Publication Number Publication Date
WO2009148600A2 WO2009148600A2 (en) 2009-12-10
WO2009148600A8 WO2009148600A8 (en) 2010-02-25
WO2009148600A3 true WO2009148600A3 (en) 2010-04-15

Family

ID=41258656

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/003391 WO2009148600A2 (en) 2008-06-06 2009-06-04 Deuterated lysine-based compounds

Country Status (1)

Country Link
WO (1) WO2009148600A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2064177B1 (en) 2006-09-21 2017-04-05 TaiMed Biologics, Inc. Protease inhibitors
PL2932970T3 (en) * 2010-01-27 2018-08-31 Viiv Healthcare Co Antiviral therapy
EP2632908B1 (en) 2010-10-29 2016-05-25 Merck Canada Inc. Sulfonamides as hiv protease inhibitors
WO2012151361A1 (en) * 2011-05-03 2012-11-08 Concert Pharmaceuticals Inc. Carbamoylpyridone derivatives
CN105315178B (en) * 2014-07-09 2018-07-06 浙江九洲药业股份有限公司 Prezista related substances and preparation method thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995026325A2 (en) * 1994-03-25 1995-10-05 Isotechnika Inc. Enhancement of the efficacy of drugs by deuteration
US20020094995A1 (en) * 1994-03-25 2002-07-18 Foster Robert T. Method of using deuterated calcium channel blockers
US6632816B1 (en) * 2002-12-23 2003-10-14 Pharmacor Inc. Aromatic derivatives as HIV aspartyl protease inhibitors
US20060025592A1 (en) * 2004-08-02 2006-02-02 Stranix Brent R Lysine based compounds
WO2006012725A1 (en) * 2004-08-02 2006-02-09 Ambrilia Biopharma Inc. Lysine based compounds
WO2006114001A1 (en) * 2005-04-27 2006-11-02 Ambrilia Biopharma Inc. Method for improving pharmacokinetics of protease inhibitors and protease inhibitor precursors
WO2007062526A1 (en) * 2005-11-30 2007-06-07 Ambrilia Biopharma Inc. Lysine-based prodrugs of aspartyl protease inhibitors and processes for their preparation
WO2008023273A2 (en) * 2006-07-17 2008-02-28 Ambrilia Biopharma Inc. Method for improving pharmacokinetics

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995026325A2 (en) * 1994-03-25 1995-10-05 Isotechnika Inc. Enhancement of the efficacy of drugs by deuteration
US20020094995A1 (en) * 1994-03-25 2002-07-18 Foster Robert T. Method of using deuterated calcium channel blockers
US20040253180A1 (en) * 1994-03-25 2004-12-16 Foster Robert T. Method of making and using isotope-substituted anti-bacterial agents
US6632816B1 (en) * 2002-12-23 2003-10-14 Pharmacor Inc. Aromatic derivatives as HIV aspartyl protease inhibitors
US20060025592A1 (en) * 2004-08-02 2006-02-02 Stranix Brent R Lysine based compounds
WO2006012725A1 (en) * 2004-08-02 2006-02-09 Ambrilia Biopharma Inc. Lysine based compounds
WO2006114001A1 (en) * 2005-04-27 2006-11-02 Ambrilia Biopharma Inc. Method for improving pharmacokinetics of protease inhibitors and protease inhibitor precursors
WO2007062526A1 (en) * 2005-11-30 2007-06-07 Ambrilia Biopharma Inc. Lysine-based prodrugs of aspartyl protease inhibitors and processes for their preparation
WO2008023273A2 (en) * 2006-07-17 2008-02-28 Ambrilia Biopharma Inc. Method for improving pharmacokinetics

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
STRANIX ET AL: "Lysine sulfonamides as novel HIV-protease inhibitors: Nepsilon-Acyl aromatic alpha-amino acids", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 16, no. 13, 1 July 2006 (2006-07-01), pages 3459 - 3462, XP005461945, ISSN: 0960-894X *

Also Published As

Publication number Publication date
WO2009148600A2 (en) 2009-12-10
WO2009148600A8 (en) 2010-02-25

Similar Documents

Publication Publication Date Title
NO2023022I1 (en) cobimetinib, optionally in any form protected by the basic patent, including harmaceutically acceptable salts and sovates thereof, particularly cobimetinib hemifumarate
WO2008024439A3 (en) 4-aminoquinazoline derivatives and methods of use thereof
ZA200806778B (en) N-Hydroxyacrylamide compounds
PT1940839E (en) Pyridopyrimidinone inhibitors of pi3kalpha
HK1147098A1 (en) Deuterated etravirine
WO2009155121A3 (en) Inhibitors of pi3 kinase
IN2012DN03085A (en)
WO2009055006A8 (en) Deuterated darunavir
WO2010108074A3 (en) Inhibitors of pi3 kinase
IN2012DN01233A (en)
PT2421879E (en) Novel 7-deazapurine nucleosides for therapeutic uses
EA201391486A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF PARKINSON'S DISEASE
MX2010008460A (en) Thiazole derivative and use thereof as vap-1 inhibitor.
UA103930C2 (en) Normal;heading 1;heading 2;heading 3;COMPOUNDS AND COMPOSITION FOR THE TREATMENT OF PARASITIC DISEASES
WO2012015986A3 (en) Substituted dioxopiperidinyl phthalimide derivatives
MX2009009238A (en) Novel phosphodi esterase inhibitors.
WO2007059154A3 (en) Treatment of cancers with acquired resistance to kit inhibitors
UA93709C2 (en) 12-imidazolyl-1-dodecanol and use thereof in the preparation of pharmaceutical compositions
MY165902A (en) Substituted pyridine derivatives as fabi inhibitors
WO2009148600A8 (en) Deuterated lysine-based compounds
WO2010019701A3 (en) Diaryl urea derivatives
WO2010047819A8 (en) Hydroxyethylamino sulfonamide derivatives
WO2010005585A3 (en) 4-aminoquinazoline prodrugs
WO2012119006A3 (en) Derivatives of pyrazole-substituted amino-heteroaryl compounds
UA98639C2 (en) Phosphodiesterase inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09758764

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09758764

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载